Samsung Biologics Takes First Step In The CMO Business While Targeting Innovative Compounds By 2017

INCHEON, South Korea - Samsung Biologics entered the first stage of a plan to become a global biopharmaceutical company, breaking ground on a biologics manufacturing plant May 27. The company hopes to establish itself as a global contract manufacturer before entering the biosimilar sector with its first entrant, a biosimilar of the monoclonal antibody Rituxan (rituximab)